---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019881"
form_type: "8-K"
ticker: null
cik: "0000764195"
company_name: "VBI Vaccines Inc/BC"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:52:28.265228+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VBI Vaccines Q1 net loss $17.9M, revenue up; new $8.5M ATM, Brii Bio deal pending

## Summary
- Net loss $17.9M ($0.73/share) vs $27.8M ($3.22) in Q1 2023; revenue $1.2M, up from $0.5M.
- PreHevbrio global net revenue $1.0M, up 105% YoY; over 80% of 2023 full-year volume sold in first 5 months of 2024.
- Entered new $8.47M ATM with H.C. Wainwright; terminated prior $125M Jefferies ATM effective May 10.
- Cash $12.6M at March 31 (down from $23.7M); subsequent ~$2.8M from offerings through early April.
- Brii Bio deal: up to $33M consideration (milestones); expects debt to reduce to ~$17M by mid-2024.

## SEC filing metadata
- accession: 0001493152-24-019881
- form_type: 8-K
- cik: 0000764195
- company_name: VBI Vaccines Inc/BC
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/0001493152-24-019881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019881
- JSON: https://secwatch.observer/filing/0001493152-24-019881.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019881.txt

## Key facts
- Earnings Releases
  VBI Vaccines Inc/BC reported financial results for the first fiscal quarter ending March 31, 2024.
  - Period: the first fiscal quarter ending March 31, 2024
  - Result: reported results
  source text: On May 15, 2024, the Company issued a press release announcing its financial results for the first fiscal quarter ending March 31, 2024, and provided a corporate update. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/0001493152-24-019881-index.htm
- Material Agreements
  VBI Vaccines Inc/BC terminated Open Market Sale Agreement with Jefferies LLC valued at Terminated prior ATM offering of up to $125,000,000 (effective 2024-05-10).
  - Action: termination
  - Agreement: equity purchase
  - Counterparty: Jefferies LLC
  - Value: Terminated prior ATM offering of up to $125,000,000
  - Effective: 2024-05-10
  source text: Effective as of May 10, 2024, the Company terminated (i) the Jefferies Sales Agreement, pursuant to Section 7(b)(i) of the Jefferies Sales Agreement, and (ii) the Prior ATM Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/0001493152-24-019881-index.htm
- Material Agreements
  VBI Vaccines Inc/BC entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $8,468,289 (effective 2024-05-15).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $8,468,289
  - Effective: 2024-05-15
  source text: On May 15, 2024, VBI Vaccines Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, common shares, no par value per share (the “Shares”), for aggregate gross proceeds of up to $8,468,289 (the “ATM Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/764195/000149315224019881/0001493152-24-019881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.